»¶ÀÖ¶·µØÖ÷_Õ©½ð»¨ÓÎÏ·

LI Jia¹, LIU Xiaoning²,ZHANG Hailong³

(1.Department of Cardiovascular, Kaifeng People¡äs Hospital,

 Kaifeng 475000, China;2. Department ofCardiovascular, Kaifeng Traditional Chinese Medicine Hospital, Kaifeng 475000, China;3. Department ofImmunology, School of Basic Medicine, Henan University, Kaifeng 475000, China)

Abstract Objective To observe the application value of indobufen tablets combined with routine antiplatelet therapy in the prevention and treatment of major adverse cardiovascular events ( MACE ) in coronary heart disease. Methods 110 patients with coronary heart disease were selected and randomly divided into two groups, with 55 cases in each group. The control group were treated with aspirin and clopidogrel, while the observation group were treated with indobufen tablets and clopidogrel. The improvement and prognosis of platelet function, coagulation function, and heart function were compared between the two groups of patients. Results After treatment, the COX-2, PAF, and ¦Â-TG levels were lower than those in the control group ( P<0.05) . APTT, PT, TT were all higher than the control group ( P <0.05) .LVEF was higher than the control group, and LVDD was lower than the control group ( P<0.05) . The incidence of MACE and drug-related side effects in the observation group was lower than that in the control group, and the difference was statistically significant ( P < 0. 05 ) . Conclusion Compared with conventional antiplatelet therapy with aspirin and clopidogrel, treatment with indobufen tablets and clopidogrel can enhance platelet function and prolong clotting time. It has a positive significance in improving patient cardiac function, reducing the risk of MACE and drug-related side effects.

Keywords: coronary heart disease; indobufen tablets; platelet function; coagulation function; clopidogrel

DOI:10.19296/j.cnki.1008-2409.2024-03-028

PDF download:click to download